Introduction
Inherited forms of retinal degeneration are relatively common causes of blindness in humans. The best characterized set of diseases causing inherited retinal degeneration is classified as retinitis pigmentosa (RP). RP affects approximately 1 in 3000 people in all ethnic groups. It is a group of retinal degenerative diseases with approximately 20% of cases inherited in an autosomal dominant fashion, 20% autosomal recessive, 13% X-linked and the remainder sporadic. Regardless of the pattern of inheritance, all patients with RP present with night blindness, progressive visual field loss and retinal degeneration. As most patients develop significant visual impairment during young adulthood, [1] [2] [3] RP imposes substantial personal and societal burdens. There is currently no cure for RP.
In recent years, mutations in a number of different genes have been implicated in the pathophysiology of RP. Our understanding of the pathogenesis caused by these mutations has increased through the discovery that several well-characterized animal models for RP possess genetic defects similar to their human counterparts. The rd mouse, for example, suffers from a spontaneous null mutation in the gene encoding the beta subunit of rodspecific cyclic GMP phosphodiesterase, ␤PDE, 4 
inherited
Advances in the identification of the genetic bases of RP have led to testing of the possibility of direct genebased intervention. Transgenic delivery of a wild-type copy of the ␤PDE cDNA to the degenerating photoreceptors of the rd mouse resulted in rescue. 10 More recently, we demonstrated that somatic delivery of recombinant adenovirus containing wild-type ␤PDE results in histological rescue of the degenerating rd photoreceptors lasting 6 weeks.
11 Adeno-associated virus-mediated delivery of wild-type ␤PDE also leads to rescue. 12 Although a disease caused by a lack-of-function mutation may be the optimal scenario for successful genetic therapy, many forms of retinal degeneration result from gain-of-function mutations. Such conditions are unlikely to be amenable to gene replacement strategies. Therefore, we investigated the possibility of interrupting the pathogenic processes secondary to the initial insult. Such an approach might provide a general treatment for retinal degeneration -one that could be used ultimately to treat patients with not only gain-of-function and lack-of-function mutations but also those in whom the exact genetic defect remains elusive (currently the majority of cases of human RP).
A secondary pathogenic process that appears to be common to all animal models of retinal degeneration examined so far, is widespread apoptotic death of photo-receptors. Apoptosis occurs in the retinal degeneration (rd) mouse, the retinal degeneration slow (rds) mouse, mice transgenic for mutant rhodopsin, the Royal College of Surgeon's (RCS) rat and in the vitiligo mouse. [13] [14] [15] [16] Apoptosis is a gene-mediated mechanism causing rapid cell death in a number of different systems, including normal development of various organs and organisms, 17, 18 T cell maturation 19 and tumor regression. 20, 21 Recently, several different genes have been identified which prevent apoptosis. One of them, bcl-2, controls apoptosis in a number of mammalian tissues. 22 Delivery of bcl-2 to neurons dying through apoptotic mechanisms has prevented apoptosis in those cells. 23, 24 To determine whether expression of bcl-2 above endogenous levels can also slow or halt apoptosis in degenerating photoreceptors, we generated a recombinant adenovirus containing rhodopsin-promoted bcl-2 (Ad.2.5HRPbcl-2). We used Ad.2.5HRPbcl-2 to test the possibility that bcl-2 can slow or halt photoreceptor degeneration in the rd retina after somatic delivery. We also used Ad.2.5HRPbcl-2 to test the possibility that co-injection of wild-type PDE␤ and bcl-2 can extend photoreceptor rescue in the rd mouse beyond that obtained by delivery of PDE␤ alone. The results reported here imply that intervention of secondary pathogenic processes in inherited retinal degeneration may be a useful strategy for treating retinal degenerations of unknown etiology or may be a useful adjunct treatment for diseases of known etiology.
Results
Cell specificity of the rhodopsin promoter in the recombinant viruses In vitro analyses: Cellular specificity of expression of transgenes directed by the rhodopsin promoter was first assessed in vitro. Since mature photoreceptors cannot be maintained for prolonged periods in culture, retinoblastoma (Y79) cells were used. Although the cellular origin of these cells is unknown, they have morphological characteristics reminiscent of photoreceptors (they form rosette-like structures) and are derived from the retina. IB3 cells (respiratory endothelial cells) were used as control. Expression derived from exposure to two different recombinant adenoviruses (Ad.1.6HRPlacZ and Ad.2.5HRPlacZ) containing different amounts of rhodopsin promoter sequence (see Materials and methods), was assessed by spectrophotometric (ONPG) assay. The control virus (Ad.CMVlacZ), containing the CMV enhancer and promoter sequence, was used as control. Thirty minutes after the start of the ONPG assay, it was apparent that only Y79 cells exposed to Ad.1.6HRPlacZ or Ad.2.5HRPlacZ possessed ␤-galactosidase (␤-gal) activity ( Figure 1 ). IB3 cells or 293 cells exposed to equivalent doses of these viruses had undetectable levels of activity. In contrast, all cells exposed to Ad.CMVlacZ possessed high levels of lacZ expression despite being exposed to one-third the number of plaque-forming units (p.f.u.) delivered with the adenoviruses containing the rhodopsin promoter.
Because the 2.5 kb upstream rhodopsin fragment resulted in high levels of photoreceptor-specific lacZ expression in vitro and in vivo in transgenic mice, 25 this fragment was used to generate a rhodopsin-promoted Figure 2a ) although occasional lacZ-expressing photoreceptors could be identified. In contrast, as shown in Figure 2b , lacZ expression in eyes injected with Ad.2.5HRPlacZ was found only in photoreceptors and not in other cells exposed to the adenovirus. This resulted in weaker staining of whole mount tissue after X-gal histochemical assay (inset to Figure 2b ). Histological analyses revealed that ␤-gal activity was especially strong in photoreceptor inner segments (arrows in Figure 2b ), similar to findings in studies of rhodopsin-promoted lacZ transgenic mice. 25, 26 The time of onset of transgene expression was determined by the choice of promoter. Transgene expression b a was detected within 48 h after injection of CMV-promoted constructs. In contrast, expression of rhodopsinpromoted transgenes was not observed until 10 days after injection. The onset of expression in juvenile mice corresponds with the time of onset of lacZ expression driven by the rhodopsin promoter activity as detected in transgenic mouse studies. 26 It should be noted that histochemical assay of lacZ expression is less sensitive than molecular biological evidence of rhodopsin promoter activity.
Expression of the bcl-2 transgene after subretinal injection of Ad.HRPbcl-2
Immunofluorescence evaluation of bcl-2 expression: Immunohistologically detectable bcl-2 expression was observed in the photoreceptor synaptic and outer nuclear layers of Ad.2.5HRPbcl-2-injected rd/rd mice 17 days after injection at age 21 days ( Figure 3A and B). Expression was detected only in the Ad.2.5HRPbcl-2-injected portion of the retina and was not detected in control retinas that were untreated or treated with Ad2.5HRPlacZ ( Figure 3C and D) or AdCMVPDE␤.
Expression of the PDE␤ transgene after subretinal injection of Ad.CMVPDE␤ RNA analyses: Reverse-transcriptase polymerase chain reaction (RT-PCR) analyses of Ad.CMVPDE␤ expression in vivo demonstrated PDE␤-specific transcripts in each rd retina injected with Ad.CMVPDE␤ as described previously. 11 There were no PDE␤ transcripts observed in control retinas or retinas injected with Ad.CMVlacZ, Ad.2.5HRPlacZ or Ad.2.5HRPbcl-2.
Evidence of photoreceptor rescue
Fundus examination: The possibility that indirect ophthalmoscopy can be used rapidly and non-invasively to
Figure 3 Immunofluorescence reveals bcl-2 expression in the outer plexiform layer and outer nuclear layer after subretinal injection of Ad.2.5HRPbcl-2. Light microscopic (A, C) and immunofluorescent (B, D) views of eyes of rd/rd mice 17 days after injection. Sections shown in (A) and (C) are hematoxylin and eosin-stained sections adjacent to those used in (B) and (D). Eyes received subretinal injection of Ad.2.5HRPbcl-2 (A, B) or Ad.CMVlacZ (C, D). Arrows indicate the OPL; onl, outer nuclear layer; inl, inner nuclear layer; gcl, ganglion cell layer. Note that the onl of Ad.HRPbcl-2-treated mice is thicker than that of Ad.CMVlacZ-treated mice; magnification, ×1000.
screen treated rd/rd eyes for therapeutic effect was examined. Qualitative assessment using ophthalmoscopy was performed 3 weeks after injection by an observer who was masked to the treatment administered. Fundus appearances of eyes treated with an experimental agent (Ad.2.5HRPbcl-2 or Ad.CMVPDE␤) were compared with those of contralateral eyes injected with a control agent (Ad.CMVlacZ). Fundus examination of lacZ-treated retinas 3 weeks after injection revealed widespread pigmentary retinopathy and thinning of retinal blood vessels ( Figure 4a ). This is similar to the appearance of an untreated rd/rd retina at the same age. In contrast, there was less pigmentary degeneration in the fundus of bcl-2-(or PDE␤)-injected rd retinas of the same age (Figure 4b ). The bcl-2-injected retinas had an appearance intermediate between that of a 6-week-old untreated rd/rd retina and a wild-type retina (Figure 4c ).
Histological evaluation: While indirect ophthalmoscopy provided a rapid and non-invasive means to assess retinal degeneration in vivo, histological measurements provided a more sensitive assessment of photoreceptor health in the rd mouse. This is because photoreceptors are terminally differentiated cells and are not replaced, after their death, by a dividing stem cell population.
Histological evaluation revealed that Ad.2.5HRPbcl-2-treated rd/rd retinas possessed two to three rows of photoreceptor nuclei 3 weeks after injection as opposed to one single row in Ad.2.5HRPlacZ-injected or untreated retinas ( Figure 5A and B). Regions of Ad.HRPbcl-2-injected retinas unexposed to the virus were indistinguishable from control or untreated retinas. The magnitude of the rescue of Ad.2.5HRPbcl-2-injected photoreceptors was not as great as after application of an equivalent dose of Ad.CMVPDE␤ ( Figure 5C ), where five rows of photoreceptor nuclei and outer segment-like structures were observed at the same time-point. Co-application of reduced (half) concentrations of Ad.2.5HRPbcl-2 and Ad.CMVPDE␤ resulted in six rows of photoreceptor nuclei (and outer segment structures) at the same time-point ( Figure 5D ). This resulted in similar appearances of retinas injected with the full dose of Ad.CMVPDE␤ and those injected with a half dose Ad.CMVPDE␤ plus Ad.2.5HRPbcl-2 (compare Figure 5C 
.5HRPbcl-2. Retinas were examined 17 days after injection (at post-natal day 21). A section of an untreated 21-day-old C57Bl/6 retina is presented for comparison (E). Labeling indicates the various layers of the wild-type retina, aligned at the ganglion cell layer (gcl) with the other sections. Inner plexiform layer (ipl), inner nuclear layer (inl), outer plexiform layer (opl), outer nuclear layer (onl), inner segments (is), outer segments (os), retinal pigment epithelium (rpe). Magnification, ×300.
and D). The widths of these layers were less than those of the untreated wild-type retina ( Figure 5E ), but were significantly greater than those in the control, Ad.2.5HRPbcl-2-injected retinas. The widths were also greater than those of rd retinas treated with half dose of either Ad.HRPbcl-2 (Bennett et al, unpublished data) or Ad.CMVPDE␤ ( Figure 6 ). Figure 6 depicts the ratio of photoreceptor nuclei in treated rd/rd retinas as compared with heterozygous (rd/+) retinas 3 weeks after birth. As demonstrated previously, 11 delivery of PDE␤ resulted in significant photoreceptor rescue (Student's t test, P Ͻ 0.0001). Ad.2.5HRPbcl-2 also increased survival as compared with untreated eyes or those treated with Ad.CMVlacZ (*Student's t test, P Ͻ 0.0001). Treatment with bcl-2 alone, however, was less effective at rescuing photoreceptor cell death than treatment with PDE␤ alone. Treatment with a mixture containing half each of the doses of Ad.2.5HRPbcl-2 and Ad.CMVPDE␤ (2.5 × 10 7 p.f.u. of each virus) resulted in survival similar to that observed with a full dose of PDE␤ alone. There was no significant difference between the extent of rescue comparing those latter two treatments (Student's t test P Ͻ 0.991). Similar to results previously reported for treatment with PDE␤, photoreceptor rescue after treatment with bcl-2, PDE␤ or a combination of the two agents persisted for approximately 6 weeks.
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There was no evidence for immune system-mediated loss of the expressing cells as there was no inflammatory cell infiltrate observed in wild-type or rd eyes injected with recombinant adenovirus or control solutions. Abnormal cellular proliferation was not observed after over-expression of bcl-2.
Discussion
We used recombinant adenoviruses to test the hypothesis that bcl-2 expression can slow or halt apoptotic cell death in photoreceptors of an animal model for RP. Effects of somatic overexpression of bcl-2 on the rate of degeneration in the rd/rd retina were assessed after microinjection of Ad.2.5HRPbcl-2 into the subretinal space. The results indicate that somatic delivery of bcl-2 causes a mild delay in photoreceptor cell death. High levels of bcl-2 expression were detected in the photoreceptor synaptic layer and photoreceptor nuclei of the retinas treated with Ad.2.5HRPbcl-2, but not the untreated or control-injected retinas. Bcl-2 expression was correlated with histological rescue. This rescue could be observed macroscopically in vivo using indirect ophthalmoscopy, which is rapid, inexpensive and non-invasive. Although the extent of rescue was not as great as that which could be achieved by application of ␤PDE alone, the findings suggest that nonspecific interventions (such those aimed at limiting apoptotic cell death) may be useful alone or in conjunction with more directed gene-based treatments in the treatment of inherited retinal degeneration. Of course, ultimately, if this sort of approach is to be used to treat humans with slowly progressing diseases such as RP, the transgene-expressing cells will have to persist for years or even decades. It may be possible to increase the stability of transgene expression through use of alternative vectors, such as adeno-associated virus or lentivirus. It will be particularly important in such studies to monitor for uncontrolled cellular proliferation that might be induced by overexpression of anti-apoptotic genes such as bcl-2. Abnormal growth characteristics were not observed in the present study.
Chen et al 27 and Joseph et al 28 previously used transgenic mouse models to examine the effects of genomically delivered bcl-2 on inherited photoreceptor degeneration. Chen et al 27 demonstrated that overexpression of bcl-2 in photoreceptors results in a reduction of apoptotic photoreceptor cell death in mice with genetically or environmentally induced retinal degeneration. In contrast, Joseph et al 28 found that overexpression of bcl-2 does not rescue photoreceptor cells from apoptosis in mice with retinal degeneration. In an attempt to reconcile these findings, we have also generated mice transgenic for bcl-2 and assessed the effect of bcl-2 on the course of photoreceptor degeneration in the rd mouse (Zeng et al, manuscript in preparation). Results from our transgenic studies were similar to those reported by Chen et al. These results are further confirmed here by the rescue effect of somatically delivered bcl-2. The lack of rescue in Joseph et al's experiments may have been due to interactions of bcl-2 with other gene products involved in the apoptotic cell death cascade, insufficient or extremely high levels of bcl-2, a lack of biological function of the bcl-2 transgene or altered cellular localization of the transgene.
In this present report, we describe the use of a photoreceptor-specific promoter in adenovirus-mediated gene therapy. A murine rhodopsin promoter shorter than the human fragment that we used (471 vs 2500 bp) was also recently found to be effective in driving photoreceptorspecific transgene expression in a recombinant adenoassociated virus. 29 Our data demonstrate that the adenovirus-delivered rhodopsin promoter directs expression of transgenes specifically to retinoblastoma cells in vitro and photoreceptors in vivo. Although the cellular origin of the Y-79 retinoblastoma cell line is unknown, these cells resemble photoreceptors morphologically. The transgene expression studies reported here indicate that Y-79 cells also possess molecular biological similarities to photoreceptors.
The ability to use a photoreceptor-specific promoter to deliver functional genes specifically to these cells in vivo minimizes the possibility that transgene expression will be toxic to neighboring cells. The fact that transgene expression was minimal after injection into adult, fully differentiated retinas, reflects the low efficiency of adenovirus-mediated transduction of the adult wild-type neural retina. 11, 30 It is probable that lacZ expression in rd/rd retinas injected with Ad.HRPlacZ was not observed because ␤-gal-derived histochemical evidence of rhodopsin promoter function is not apparent until approximately 9 days after birth (see Results) 25,26 about the time that photoreceptors in the rd mouse begin to undergo massive degeneration. The fact that mild photoreceptor rescue is observed after treatment of rd/rd retinas with Ad.2.5HRPbcl-2 suggests that the rhodopsin promoter activates close to the time that the photoreceptors begin to undergo massive apoptotic cell death. It also indicates that bcl-2 is effective at blocking apoptosis not only in damaged neurons in the central nervous system but also in the retina. The rescue achieved by the rhodopsin-promoted bcl-2 construct is particularly impressive considering the low efficiency of transduction of retinal photoreceptors by recombinant adenovirus. In this particular system, an added advantage is that the adenovirus must be delivered at neonatal time-points to achieve rescue. It is likely that neonatal delivery, which significantly increases the efficiency of adenovirus-mediated photoreceptor transduction, 30 enhances rescue of the photoreceptors. In discussing the rescue effects of bcl-2, it is important to point out that, in experiments involving co-injections of Ad2.5.HRPbcl-2 and Ad.CMVPDE␤, we did not control for the use of the two different promoters. However, preliminary data from experiments in progress in our laboratory using lacZ and PDE␤-containing recombinant adenoviruses, indicate that there is no significant interplay between the HRP and CMV promoters in retinal cells.
One issue that was not addressed in the current study is whether the application of bcl-2 rescues rod or cone photoreceptors preferentially. Although the bcl-2 transgene used here was driven by the rhodopsin (rodspecific) promoter, it is possible that the promoter was leaky and that bcl-2 was also expressed in cone photoreceptors. Alternatively, rescue of rod photoreceptors mediated through expression of the bcl-2 in those cells, may have indirectly rescued the cone photoreceptors. Modulation of rod photoreceptors with the goal of rescuing cones themselves may be a worthy goal of gene therapy for inherited retinal degeneration. Regarding rescue of cones, it should be noted that recent studies by LaVail et al 31 demonstrate an unexpected hemispheric asymmetry (with more cones surviving in the inferior hemisphere) and great variability in the number of surviving cones in the rd mouse retina apparent 8-9 weeks after birth. Because all of our injections (and thus photoreceptor cell counts) were performed in the superior hemispheres of rd retinas and because our studies extended only 7 weeks after birth, we do not believe that this finding complicates our results. Studies are in progress, however, to examine the extent of rescue according to photoreceptor sub-type.
The findings reported here add to the substantial data already accumulated regarding the ability of bcl-2 to protect neurons undergoing degeneration. 24, [32] [33] [34] [35] It is possible that application of bcl-2 driven by a viral promoter would extend the rescue effect for two reasons: the onset of viral-promoted transgene expression would precede the onset of photoreceptor cell death; higher levels of transgene expression are observed using a viral promoter than a rhodopsin promoter (see Figure 1) . This possibility could not be tested, as we were unable to generate a CMV-promoted bcl-2 containing adenovirus. This may be due to toxicity of bcl-2 in the cells used to generate the recombinant virus or interference of bcl-2 expression with viral plaque formation. Interference with viral plaque formation would not have been a problem in the generation of Ad.2.5HRPbcl-2 as the rhodopsin promoter does not drive transgene expression in the 293 cells used to generate recombinant adenoviruses.
In summary, somatic delivery of a gene that slows programmed cell death is capable of rescuing degenerating photoreceptors. This may have application to gene therapy of retinal diseases such as RP. Such an approach could potentially be applied to diseases caused by gainof-function or loss-of-function mutations and even forms of the disease with unknown etiology. As most patients develop significant visual impairment during young adulthood, RP imposes substantial personal and societal burdens. The ability to halt the progression of retinal degeneration could lead to an effective treatment for blinding diseases such as RP.
Materials and methods
Generation of recombinant adenovirus Adenovirus vectors were prepared, purified and titered to 10 12 to 10 13 particles/ml as described. 36 The same stocks of adenoviruses were used for all experiments. All manipulations of adenoviral vectors were done according to institutional and national biosafety restrictions.
pAd2.5HRPlacZ contains the E. coli lacZ gene driven by the same 2.5 kb human rhodopsin upstream fragment used to generate pAd.2.5HRPbcl-2. It was prepared by first isolating a SpeI/XbaI fragment from p5.3HRPlacZ. 37 This fragment contains the 2.5 kb region immediately upstream to the human rhodopsin gene and the bacterial lacZ gene. This 2.5 kb rhodopsin upstream fragment and the 1.6 kb fragment described below were selected because they had been previously shown to drive high levels of photoreceptor-specific reporter gene expression in transgenic mice (Ref. 25 and Bennett, manuscript in preparation). The 2.5 kb fragment was ligated into the BglII site of pAd.BglII. pAdBglII, generously provided by J Wilson (Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, PA, USA), contains regions corresponding to adenovirus 5 map units 0 to 1.0 and 9.2 to 16.1 separated by a multiple cloning site. The Ad 0-1 and human rhodopsin promoted-lacZ segments were then ligated into Ad.CMVLink after digestion of each with NheI and SalI.
pAd1.6HRPlacZ was generated as described for pAd2.5HRPlacZ except that a BglII/XbaI fragment from p5.3HRPlacZ (produced after partial digestion) was ligated into the BglII site of pAd.BglII. This fragment contains the 1.68 kb region immediately upstream to the human rhodopsin gene and the bacterial lacZ gene.
Ad.CMVlacZ contains the lacZ gene driven by the cytomegalovirus (CMV) promoter. Ad.CMVPDE␤ contains the wild-type murine cDNA for the beta subunit of rod photoreceptor-specific phosphodiesterase driven by the CMV promoter. 11 pAd.2.5HRPbcl-2 contains the human cDNA encoding bcl-2 driven by the 2.5 kb fragment immediately upstream to the human rhodopsin gene. The bcl-2 cDNA was isolated by digesting pNB18-BS5, which contains neurofilament-promoted bcl-2 cDNA (and the 2.85 kb human growth hormone splice donor/acceptor and poly(A+) sequence), with SalI and SpeI. The SpeI-cut end was filled in to generate a blunt end. The resultant 2.85 kb fragment was inserted into pAd.2.5HRPLink that had been digested with XhoI and EcoRV.
The recombinant viruses were generated through homologous recombination of Ad5 strain dl7001. This strain is deleted of E1 and the majority of the E3 region (3.2 kb). Recombinants were obtained in 293 cells and, after isolation of viral DNA, were identified with Southern blot analysis. Attempts were made to generate a recombinant bcl-2-containing virus containing a CMV promoter, however these were unsuccessful.
The ratio of p.f.u. to total virion particles for each of the new recombinant generated was 50. Stocks of each of the new recombinants were evaluated for contamination with replication-competent adenovirus by PCR. Primers specific for the adenovirus E1a region (which is deleted in the recombinants but present in the wild-type virus) were used for this purpose. A similar strategy could have also been used to screen for E1b which is also devoid in the recombinant viruses. Nucleotide sequence of the primers was generously provided by X Ye (Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, PA, USA) and was as follows: forward: TCGAA-GAGGTACTGGCTGAT; reverse: TGACAAGACCTGCA ACCGTG. A total of 35 PCR cycles were performed in an MJ Research thermal cycler with an initial denaturation of 7 min at 95°C, denaturation temperature of 94°C for 1 min, annealing temperature of 55°C for 1 min, extension temperature of 72°C for 1 min and a final extension of 10 min at 72°C. All recombinant stocks used lacked the E1a region. 7 p.f.u. of adenovirus) was accomplished through a transscleraltranschoroidal approach as described previously. 11, 38 Controls for the Ad.CMVPDE␤ plus Ad.2.5HRPbcl-2 injections were performed using half the number of p.f.u. of either Ad.CMVPDE␤ or Ad.2.5HRPbcl-2 (see below). Half-doses (ie 2.5 × 10 7 p.f.u.) were selected for combination treatments in order to keep the total dose (in p.f.u.) of virus constant in each injection. All injections were monitored by indirect ophthalmoscopy and by direct visualization through the operating microscope. Visualization of the retinal detachment confirmed that the transfection solution was injected into the targeted location. All injections in which blebs were not successfully raised were noted and analyzed separately. Experiments were repeated three times.
Evaluation of retinas by indirect ophthalmoscopy
Mice were anesthetized with avertin (2,2,2-tribromoethanol, 0.5-0.6 g/kg intraperitoneally; Aldrich Chemical, Milwaukee, WI, USA) and their pupils were dilated with topically applied 0.5% tropicamide. Indirect ophthalmoscopy was performed using a 90 diopter lens. Photographs were made using a Kowa camera (Keeler Instruments, Broomall, PA, USA).
Evaluation of retinas by light microscopy At necropsy, a 30-gauge needle was used to puncture the nasal aspect of the cornea of the enucleated eyes and the eyes were fixed immediately for 1 h at 4°C in PBS pH 7.5 containing 4% paraformaldehyde. The needle puncture served as a reference point later to delineate the superior and inferior quadrants of all eyes as well as the injection site in eyes receiving virus. The injection site was in the temporal aspect of each eye, 180°opposite the corneal puncture mark.
After post-fixing for 24 h in a solution containing 2.5% glutaraldehyde, 1% formaldehyde, 0.1 m Na cacodylate (pH 7), a sclerotomy was performed on the nasal aspect of each eye. The sclerotomy facilitated orientation of the specimens for sectioning. Samples were dehydrated and embedded in paraffin or plastic. Those samples designated for plastic sectioning were postfixed in 1% osmium tetroxide before dehydration and embedded in resin containing 14.5% Epon (Embed 812; Electron Microscopy Sciences, Fort Washington, PA, USA) and 2% 2,4,6-tri(dimethylamine methyl) phenol (DMP 30; Tousimis Research, Rockville, MD, USA), 28.6% araldite 502 (Electron Microscopy Sciences) and 56.9% dodecenylsuccinic anydride (Polyscience, Warrington, PA, USA). Specimens were sectioned with the blade oriented perpendicular to the injection (and sclerotomy) site. Paraffinembedded samples were sectioned at 5 m. Paraffin was removed and sections were counterstained with either hematoxylin and eosin or neutral red. Plastic-embedded sections were sectioned at 1.0 m using an RMC MT7000 Ultramicrotome. Sections were then counterstained with toluidine blue (1%) in 1% sodium borate.
Histochemical analysis of lacZ expression
Those eyes which were reacted for ␤-gal activity were fixed for 1 h with 4% paraformaldehyde in PBS (pH 7.2), washed with PBS and reacted for 12 h with 1 mg/ml of X-gal (5-bromo-4-chloro-3 indolyl ␤-d-galactoside; Sigma Chemical, St Louis, MO, USA) as described previously. 38, 39 Detection of the blue X-gal reaction product was used to assess expression of the lacZ gene product, ␤-gal, with or without counterstaining with hematoxylin and eosin.
Solution assay of lacZ expression
Cell extracts were incubated in 440 l of 0.23 g/l o-nitrophenyl-␤-d-galactopyranoside (ONPG; Sigma Chemical) in 100 mm phosphate buffer (pH 7.0) containing 80 mm sodium phosphate, 8 mm potassium chloride, 0.8 mm magnesium sulfate and 35 mm 2-mercaptoethanol at 37°C. Thirty minutes later, 550 l of 1 m sodium carbonate was added to stop the reaction. Absorbance was measured at 420 nm with a Beckman DU 640 spectrophotometer (Columbia, MD, USA). Experiments were repeated three times.
Histological analyses
For retinal analyses, specific cell types were identified on the basis of their location within the well-defined cell layers of this structure. Inflammatory response was assessed by examination of hematoxylin and eosin-stained sections.
Assessment of the extent of retinal degeneration was made by comparison of numbers of photoreceptor nuclei in portions of experimental vs control retinas as a function of age (or time after injection of recombinant adenovirus). Counts of photoreceptor nuclei at six different sites (separated by four to five cell-length increments) in the mid-peripheral temporal region of the retinas were made. For adenovirus-treated retinas, measurements were made in the center of the injection site and in the uninjected portion of the retina. Measurements were made by one investigator who was masked as to the material that had been injected. Average numbers of photoreceptor nuclei were compared by the Student's t test.
Detection of bcl-2 transgene expression
Immunofluorescence for bcl-2 expression: Eyes were fixed in 4% paraformaldehyde in PBS for 1 h, 10, 20 and 30% sucrose in PBS (each concentration for at least 6 h), embedded in Optimal Cutting Temperature compound (OTC; Baxter Scientific, Edison, NJ, USA) and frozen in liquid nitrogen. Tissue was sectioned at 12 m and immunofluorescence was performed to identify bcl-2-expressing cells. Before blocking with goat serum, steam antigen retrieval in 0.01 mol/l citrate buffer, pH 6.0 was performed through modification of techniques described by Bronner et al. 40 The primary antibody, polyclonal rabbit ␣-bcl-2 (N-19; Santa Cruz Biotechnology, San Diego, CA, USA) was applied at 2 g/ml. Secondary antibody was fluorescein-conjugated goat anti-rabbit (Vector Laboratories, Burlingame, CA, USA) and was applied at 12 g/ml. Negative controls included tissue processed without application of primary antibody or after application of an irrelevant antibody and untreated retinas. Positive controls consisted of paraffin-embedded sections from a human gastrointestinal adenocarcinoma (generously provided by E Furth, Department of Pathology, University of Pennsylvania, Philadelphia, PA, USA). Assessment of antibody staining was performed using a Nikon Diaphot microscope equipped with fluorescence and Hoffman modulation contrast optics (Optical Apparatus, Ardmore, PA, USA).
Detection of PDE␤ transgene expression
Total RNA was extracted from each of five individual rd/rd retinas injected with each of the recombinant (bcl-2-, PDE␤-or lacZ-containing) viruses or combinations thereof and assayed by RT-PCR amplification for ␤PDE-specific transcripts. Methods were as described previously.
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